Nanopartículas de PLGA-quitosana contendo dexametasona: desenvolvimento, caracterização e avaliação da atividade anti-inflamatória in vitro
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
Abstract
The objective of this work was to develop and characterize nanoparticles (NP)
consisting of PLGA and coated with chitosan (QT) for the encapsulation of
dexamethasone (DEX), aiming to increase the efficacy of this drug in the context of
the treatment of severe acute respiratory syndrome (SARS) related to COVID-19. For
this purpose, DEX acetate (DEXAc) or DEX disodium phosphate were used for the
development of PN. The use of DEXAc provided greater encapsulation efficiency
(EE) of the drug in the PN and, therefore, this formulation was chosen for subsequent
trials. NP-DEXAc were coated with QT (NP-DEXAc-QT) and characterized in relation
to mean hydrodynamic diameter (DHm), polydispersity index (PdI), zeta potential
(PZ), morphology, encapsulation efficiency (EE) and drug loading (DL). In addition,
X-ray diffraction (XRD) and Fourier transform infrared spectroscopy (FTIR) analyzes
were conducted. Cytotoxicity in J774.A1 strain (murine macrophages) and in vitro
anti-inflammatory activity after stimulation of these strain with LPS or LPS+IFN-γ and
subsequent quantification of nitric oxide (NO), IL-6, IL- 12 and TNF-α were also
evaluated. The developed formulations showed characteristics of monodisperse
systems (PdI < 0.3). The DHm of NP-DEXAc-QT (264.4 ± 4.4 nm) was higher than
that obtained for NP-DEXAc (207.3 ± 6.7 nm). Furthermore, after coating, there was
an inversion of the PZ of the NP-DEXAc (-11.83 ± 1.4 mV) to positive values (+30.0 ±
1.6 mV). Furthermore, the microscopy analyzes showed that the coating made the
surface of the PN smoother. Analyzed together, these data may indicate that the NP
were efficiently coated by QT. The EE was high for both formulations, with results
equal to 83.7 ± 1.04% (LD = 6.96 ±0.09%) for NP-DEXAc and 78.5 ± 0.26% (DL =
6.53 ± 0.02%) for QT-DEXAc-NP. DRX and FTIR analyzes confirmed the
encapsulation of DEXAc within the polymeric matrix, as well as the occurrence of NP
coating by QT. There was no evidence of cytotoxicity up to concentrations of 200
µg/mL and 400 µg/mL for DEXAc-NP and QT-DEXAc-NP, respectively. This result
may indicate that CT increases the cells' tolerance to nanoparticles. Regarding the
anti-inflammatory activity, the NP-DEXAc-QT provided a significant reduction in the
levels of NO and cytokines compared to the control group (stimulated and untreated
cells), in addition to presenting a comparable effect to the free drug. Thus, the results
obtained indicate that QT-coated nanoparticles have promising characteristics for the
delivery of DEXAC aimed at application in the treatment of SARS associated with
COVID-19.
Description
Keywords
Citation
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

